Date: 2013-12-17
Type of information: Licensing agreement
Compound: AGE1.CR® Cell Line
Company: ProBioGen (Germany) Emergent BioSolutions (USA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: AGE1.CR® is an immortalized cell line derived from primary cells of a Muscovy Duck. The cell line was created as a platform for replacing primary chicken cells for production of vaccines and hyper-attenuated viruses in chemically defined media and suspension cultures. In addition, AGE1.CR® cells are also suitable for the generation of trans-complementing helper or packaging cell lines to support efficient production of replication-restricted viral vectors.
Disease:
Details: * On December 17, 2013, ProBioGen has announced that it has signed an agreement with Emergent BioSolutions for a non-exclusive commercial multi-product license and option agreement under which Emergent will be granted broad access to ProBioGen’s avian AGE1.CR® cell line. Previously, ProBioGen had granted an exclusive license to Emergent for four indications and also conducted process development work for Emergent. As a result of the new agreement, ProBioGen’s relationship with Emergent is now extended to include additional infectious disease targets, with the option to expand to numerous further indications.
Financial terms: The commercial licenses include milestones and royalty payments. Financial details were not disclosed.
Latest news:
